Advisor Partners LLC cut its stake in Cooper Companies Inc (NYSE:COO) by 8.1% in the first quarter, HoldingsChannel.com reports. The fund owned 1,311 shares of the medical device company’s stock after selling 116 shares during the period. Advisor Partners LLC’s holdings in Cooper Companies were worth $388,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc grew its stake in shares of Cooper Companies by 0.6% in the third quarter. Vanguard Group Inc now owns 5,041,468 shares of the medical device company’s stock worth $1,397,243,000 after acquiring an additional 31,280 shares during the period. BlackRock Inc. grew its position in Cooper Companies by 7.1% during the fourth quarter. BlackRock Inc. now owns 3,732,729 shares of the medical device company’s stock valued at $949,981,000 after buying an additional 246,088 shares during the period. Geode Capital Management LLC grew its position in Cooper Companies by 9.7% during the fourth quarter. Geode Capital Management LLC now owns 721,796 shares of the medical device company’s stock valued at $183,414,000 after buying an additional 63,889 shares during the period. Northern Trust Corp grew its position in Cooper Companies by 3.7% during the fourth quarter. Northern Trust Corp now owns 588,406 shares of the medical device company’s stock valued at $149,749,000 after buying an additional 20,854 shares during the period. Finally, WCM Investment Management LLC grew its position in Cooper Companies by 7.2% during the fourth quarter. WCM Investment Management LLC now owns 531,853 shares of the medical device company’s stock valued at $135,356,000 after buying an additional 35,812 shares during the period.
Several analysts recently issued reports on COO shares. Goldman Sachs Group lowered shares of Cooper Companies from a “neutral” rating to a “sell” rating and cut their target price for the company from $233.00 to $221.00 in a research report on Friday, January 4th. William Blair restated an “outperform” rating on shares of Cooper Companies in a research report on Saturday, January 12th. Stephens upgraded shares of Cooper Companies from an “equal weight” rating to an “overweight” rating and set a $305.00 target price for the company in a research report on Friday, February 1st. Zacks Investment Research lowered shares of Cooper Companies from a “hold” rating to a “sell” rating in a research report on Tuesday, February 5th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $325.00 target price on shares of Cooper Companies in a research report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company’s stock. Cooper Companies currently has a consensus rating of “Buy” and an average price target of $307.90.
Shares of NYSE COO opened at $288.30 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.27 and a quick ratio of 0.75. The company has a market cap of $14.16 billion, a P/E ratio of 25.07, a price-to-earnings-growth ratio of 2.22 and a beta of 0.88. Cooper Companies Inc has a 12-month low of $221.50 and a 12-month high of $302.36.
Cooper Companies (NYSE:COO) last posted its quarterly earnings results on Tuesday, March 5th. The medical device company reported $2.88 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.50 by $0.38. The business had revenue of $628.10 million during the quarter, compared to analyst estimates of $618.50 million. Cooper Companies had a net margin of 14.22% and a return on equity of 17.56%. Equities research analysts anticipate that Cooper Companies Inc will post 12.01 EPS for the current year.
About Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Featured Story: Leveraged Buyout (LBO)
Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cooper Companies Inc (NYSE:COO).
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.